Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) announced the completion of Phase 1 clinical studies for its lead candidate LUCID-MS, a patented therapeutic designed to address demyelination and provide neuroprotection in multiple sclerosis (MS). The company reported that the therapy demonstrated a favorable safety profile and was generally well tolerated among healthy volunteers. This milestone follows the submission of an Investigational New Drug application to the U.S. Food and Drug Administration in April 2026.
Multiple sclerosis is a chronic autoimmune and neurodegenerative disease affecting more than 2.8 million people worldwide, including approximately 1 million in the United States. The condition arises when the immune system attacks myelin, the protective sheath surrounding nerve fibers in the brain and spinal cord, leading to disrupted nerve communication and symptoms such as loss of mobility and bodily control. Current treatments primarily focus on reducing inflammation and relapse frequency but often fail to address the underlying neurodegeneration and myelin damage that drive long-term disease progression.
Quantum BioPharma’s LUCID-MS program targets this unmet need by aiming to directly protect or restore myelin integrity. According to the company, there are no approved therapies that effectively halt or reverse the progressive loss of myelin in MS patients. The advancement of LUCID-MS into later-stage clinical trials could represent a significant shift in MS treatment paradigms, offering hope for improved outcomes in mobility and quality of life.
The company’s recent progress underscores the potential for neuroprotective and remyelinating therapies in MS. For further updates, investors can access the company’s newsroom at https://ibn.fm/QNTM. The information in this article is based on a press release disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN, focuses on developments in the biotechnology and life sciences sectors. More details are available at https://www.BioMedWire.com. For full terms and disclaimers, visit https://www.BioMedWire.com/Disclaimer.
